Treatment of Fluid Overload from Pulmonary Hypertension

Initial Management Approach

Diuretics are the cornerstone of treatment for fluid overload in pulmonary hypertension, with careful monitoring of electrolytes and renal function to avoid complications, as recommended by the European Respiratory Society 1
The primary goal of therapy must be to improve global management of the underlying condition before considering specific measures to treat pulmonary hypertension, according to the European Respiratory Society 2
Optimize volume status, which is of critical importance in severe heart failure and may require invasive monitoring in some cases, as suggested by the European Respiratory Society 2, 3

Diuretics are essential for symptomatic relief in fluid-overloaded patients with pulmonary hypertension, as stated by the European Respiratory Society and the European Heart Society 1, 4
Loop diuretics should be used initially for patients with significant fluid overload, usually given intravenously if hospitalized, as recommended by the American Heart Association 5
The choice and dose of diuretic therapy should be tailored based on the severity of fluid overload and patient response, according to the European Respiratory Society 1
Consider adding aldosterone antagonists to the diuretic regimen, with systematic assessment of electrolyte plasma levels, as suggested by the European Respiratory Society 1
Some patients may benefit from non-specific vasodilators such as nitrates and hydralazine, although evidence supporting this strategy is limited, as noted by the European Respiratory Society 2, 3

Monitor renal function and blood biochemistry to avoid hypokalaemia and the effects of decreased intravascular volume leading to pre-renal failure, as recommended by the European Respiratory Society 1
Perform daily weight measurements, track fluid input/output, and assess vital signs (both supine and standing) during active diuresis, as suggested by the American Heart Association 5
Regularly evaluate electrolytes, especially in patients on combination diuretic therapy, as recommended by the European Respiratory Society and the European Heart Society 1, 4
Angiotensin-converting enzyme inhibitors, angiotensin-2 receptor antagonists, beta-blockers, and ivabradine are not recommended in PAH patients unless required for comorbidities, as stated by the European Respiratory Society 1

In severe cases, hospitalization in an intensive care unit is recommended for patients with signs of hemodynamic compromise, as suggested by the European Heart Society 6
For patients with inadequate response to maximal medical therapy, consider referral for lung transplantation evaluation, as recommended by the European Heart Society 6
Consider supervised exercise rehabilitation for physically deconditioned patients, as suggested by the European Heart Society 7, 4

For patients with PAH associated with left heart disease, repair of valvular heart disease and aggressive therapy for heart failure with reduced systolic function should be prioritized, as recommended by the European Respiratory Society 2, 3
Identify and treat concomitant disorders that may contribute to pulmonary hypertension, including COPD, sleep apnea syndrome, and pulmonary embolism, as suggested by the European Respiratory Society 2, 8